A single center, phase I, partially blinded, placebo-controlled, first-in-man study to evaluate the safety, tolerability and Proof of Mechanism (PoM) of a single administration of BFH772 in healthy volunteers, and Proof of Concept (PoC) study to evaluate the safety, tolerability, and pharmacodynamics of multiple topical administrations of BFH772 in patients with psoriasis

Trial Profile

A single center, phase I, partially blinded, placebo-controlled, first-in-man study to evaluate the safety, tolerability and Proof of Mechanism (PoM) of a single administration of BFH772 in healthy volunteers, and Proof of Concept (PoC) study to evaluate the safety, tolerability, and pharmacodynamics of multiple topical administrations of BFH772 in patients with psoriasis

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Jun 2013

At a glance

  • Drugs Betamethasone/calcipotriol (Primary) ; Betamethasone-dipropionate/calcipotriol
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Jun 2013 New source identified and integrated (European Clinical Trials Database: EudraCT2008-002795-96).
    • 03 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Oct 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top